Modality
ERT
MOA
Anti-Tau
Target
AuroraA
Pathway
Tau
AngelmanCeliac
Development Pipeline
Preclinical
~Jan 2022
→ ~Apr 2023
Phase 1
~Jul 2023
→ ~Oct 2024
Phase 2
Jan 2025
Phase 2Current
NCT07685406
570 pts·Celiac
2025-01→2025-01·Recruiting
570 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-081.2y agoPh3 Readout· Celiac
Trial Timeline
2025
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-01-08 · 1.2y ago
Celiac
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07685406 | Phase 2/3 | Celiac | Recruiting | 570 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |